Law firms Bleichmar Fonti & Auld LLP and Bronstein, Gewirtz & Grossman, LLC filed a class-action lawsuit against GRAIL, Inc. The suit alleges GRAIL and its senior executives committed securities fraud through misleading statements about the NHS-Galleri cancer trial.
GRAIL shares plummeted 50.55% on February 20, 2026. This decline occurred after the company revealed the trial failed to significantly reduce late-stage cancers.
The lawsuit claims management misrepresented the trial's likelihood of success. The lead plaintiff deadline is set for August 4, 2026.